GLP-1 agonists directly enhance insulin secretion by binding to GLP-1 receptors on pancreatic cells. In addition to promoting hypoglycemic effects, they can increase the number of cells in the pancreas, block cell death, and boost insulin production [90], [91].
This review delves into the physiological roles of GLP-1, exploring its impact on glucose homeostasis, insulin secretion, and satiety. We examine the compelling evidence supporting GLP-1 receptor agonists (GLP-1RAs) in managing type 2 diabetes (T2D), obesity, and other diseases.
GLP-1 not only promotes the release of insulin but also enhances the response of pancreatic -cells to insulin through the PI3K/Akt pathway, thereby improving insulin signal transduction...
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Receptor Activation And Insulin Dependence.
GLP-1 influences key secretagogues and intracellular mediators (calcium, glutamate, -aminobutyric acid, serotonin, and urocortin-3), with complex roles in insulin exocytosis. Additionally, we discuss the interplay between calcium and cAMP, and how GLP-1 modulates both pathways to coordinate insulin secretion.
The discovery of glucagon-like peptide-1 (GLP-1) is largely credited to Svetlana Mojsov, who in 1983 isolated a fragment from the preproglucagon gene capable of stimulating insulin secretion, later recognized as GLP-1 [1]. Although this endogenous hormone showed great promise for treating type 2 diabetes (T2DM) due to its ability to stimulate insulin release in a glucose-dependent manner, its ...
